Revvity rises after quarterly profit and sales beat estimates

Medical equipment maker Revvity's RVTY.N shares rise 8.2% to $102 premarket

RVTY posts Q1 profit and revenue above Wall Street estimates and maintains its full-year profit forecast, helped by steady demand from biotech clients for medical equipment used for drug research

Company posts a Q1 adj. profit of $1.01 per share, above analysts' estimates of 95 cents, according to data compiled by LSEG

It reported Q1 revenue of $664.8 million, slightly above estimates of $661.2 million

Company maintains annual profit forecast of $4.90 to $5 per share on an adjusted basis

RVTY now sees 2025 revenue to be between $2.83 billion and $2.87 billion, compared with the previous projection of $2.80 billion to $2.85 billion

Up to last close, stock had fallen 15.5% YTD